Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Screener

OTLK

Outlook Therapeutics Inc

May 16 • 04:00PM ET

7.33

Dollar change -0.10
Percentage change -1.35	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWO VTWO IWC VTWG RYLD IWV VTHR

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-11.48	Insider Own	29.33%	Shs Outstand	23.30M	Perf Week	-5.17%
Market Cap	170.79M	Forward P/E	-	EPS next Y	-2.08	Insider Trans	0.95%	Shs Float	16.47M	Perf Month	-14.87%
Income	-159.13M	PEG	-	EPS next Q	-0.88	Inst Own	32.39%	Short Float	7.64%	Perf Quarter	-24.40%
Sales	0.00M	P/S	-	EPS this Y	29.97%	Inst Trans	-24.34%	Short Ratio	1.85	Perf Half Y	-16.70%
Book/sh	-6.10	P/B	-	EPS next Y	38.22%	ROA	-281.52%	Short Interest	1.26M	Perf Year	-69.20%
Cash/sh	2.03	P/C	3.62	EPS next 5Y	-	ROE	-827.71%	52W Range	4.00 - 40.60	Perf YTD	-6.98%
Dividend Est.	-	P/FCF	-	EPS past 5Y	52.49%	ROI	-	52W High	-81.95%	Beta	0.65
Dividend TTM	-	Quick Ratio	1.07	Sales past 5Y	12.77%	Gross Margin	-	52W Low	83.07%	ATR (14)	0.63
Dividend Ex-Date	-	Current Ratio	1.07	EPS Y/Y TTM	-128.91%	Oper. Margin	0.00%	RSI (14)	35.54	Volatility	6.20% 6.43%
Employees	24	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.14	Target Price	39.86
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	-1444.33%	Payout	-	Rel Volume	0.59	Prev Close	7.43
Sales Surprise	-	EPS Surprise	-70.35%	Sales Q/Q	-	Earnings	May 16 BMO	Avg Volume	680.36K	Price	7.33
SMA20	-10.38%	SMA50	-12.40%	SMA200	-27.60%	Trades		Volume	399,568	Change	-1.35%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-27-24	Upgrade	BTIG Research	Neutral → Buy	$50
Feb-15-24	Upgrade	Chardan Capital Markets	Neutral → Buy	$3
Jan-25-24	Upgrade	Guggenheim	Neutral → Buy
Dec-27-23	Upgrade	CapitalOne	Equal Weight → Overweight	$5
Aug-31-23	Downgrade	H.C. Wainwright	Buy → Neutral	$5 → $1
Aug-31-23	Downgrade	Chardan Capital Markets	Buy → Neutral
Aug-30-23	Downgrade	Guggenheim	Buy → Neutral
Aug-30-23	Downgrade	CapitalOne	Overweight → Equal Weight
Aug-30-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$4.50 → $1
Aug-30-23	Downgrade	BTIG Research	Buy → Neutral
Jul-13-23	Initiated	CapitalOne	Overweight	$5
Apr-03-23	Initiated	Guggenheim	Buy	$5
Feb-06-23	Initiated	Cantor Fitzgerald	Overweight	$4
Oct-31-22	Initiated	BTIG Research	Buy	$7
Sep-13-22	Initiated	Chardan Capital Markets	Buy	$10
Sep-11-19	Initiated	Ladenburg Thalmann	Buy	$9
May-16-19	Initiated	Oppenheimer	Outperform	$12
Apr-22-19	Initiated	Ascendiant Capital Markets	Buy

Show Previous Ratings

May-15-24 10:53PM	OTLK Stock Earnings: Outlook Therapeutics Misses EPS for Q2 2024 (InvestorPlace)
05:00PM	Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate Update (GlobeNewswire)
May-13-24 11:18AM	Outlook Therapeutics Submits Marketing Application for Wet Age-related Macular Degeneration Therapy in UK (MT Newswires)
08:50AM	Outlook Therapeutics Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD (GlobeNewswire)
May-09-24 08:45AM	Outlook Therapeutics to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and Webcast (GlobeNewswire)
09:05AM	Loading…
May-02-24 09:05AM	Outlook Therapeutics to Present at the Retina World Congress 2024 (GlobeNewswire)
Apr-29-24 09:00AM	Outlook Therapeutics to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase (GlobeNewswire) +7.95%
Apr-26-24 06:37AM	Marriott Vacations, Carrols Restaurant Group, and More Stocks See Action From Activist Investors (Barrons.com)
Apr-15-24 04:15PM	Outlook Therapeutics Announces Closing of Private Placement of $5.0 Million (GlobeNewswire)
12:54PM	Biotech on a Budget: 7 Stocks Under $10 With Huge Potential (InvestorPlace)
Apr-10-24 03:30PM	Insiders are Piling into These 10 Healthcare Stocks in 2024 (Insider Monkey)
Mar-22-24 07:35AM	Outlook Therapeutics Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD (GlobeNewswire) +22.59%
Mar-18-24 05:10PM	Outlook Therapeutics Announces Closing of Private Placement of up to $159 Million (GlobeNewswire) -5.52%
Mar-12-24 08:05AM	Outlook Therapeutics Announces Effective Date for 1-for-20 Reverse Stock Split (GlobeNewswire) -10.57%
Mar-06-24 03:36PM	7 of the Best Speculative Stocks You Can Snag for Less Than $1 (InvestorPlace)
01:37PM	Loading…
Feb-25-24 01:37PM	7 Biotech Penny Stocks on the Verge of Clinical Trial Victory (InvestorPlace)
Feb-14-24 05:27PM	Outlook Therapeutics Inc (OTLK) Reports Q1 Fiscal 2024 Results and Strategic Developments (GuruFocus.com) +5.08%
08:05AM	Outlook Therapeutics Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate Update (GlobeNewswire)
Jan-31-24 08:05AM	Outlook Therapeutics Doses First Subject in NORSE EIGHT (GlobeNewswire) -6.99%
Jan-24-24 08:06AM	Outlook (OTLK) Surges 31% on Regulatory Update for AMD Study (Zacks) -9.87%
Jan-23-24 08:00AM	Outlook Therapeutics Receives FDA Agreement Under Special Protocol Assessment (SPA) for 90 Day Non-Inferiority Study, NORSE EIGHT, and Announces Private Placement of Up to $172 Million to Advance ONS-5010 (GlobeNewswire) +30.53%
Jan-02-24 10:18PM	Outlook Therapeutics Investors: Company Investigated by the Portnoy Law Firm (GlobeNewswire)
Dec-27-23 02:03PM	OTLK Stock Earnings: Outlook Therapeutics Reported Results for Q4 2023 (InvestorPlace)
09:30AM	OUTLOOK SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Outlook To Contact Him Directly To Discuss Their Options (GlobeNewswire)
Dec-26-23 02:15PM	January 2. 2024 Lawsuit Deadline: Investors who lost over $200,000 with Outlook Therapeutics, Inc. (NASDAQ: OTLK) shares should contact the Shareholders Foundation (GlobeNewswire) +5.41%
Dec-22-23 08:05AM	Outlook Therapeutics Reports Financial Results for Fiscal Year 2023 and Reiterates ONS-5010 Clinical and Regulatory Path Forward in the U.S. and EU (GlobeNewswire)
Dec-19-23 08:05AM	Outlook Therapeutics Submits Special Protocol Assessment (SPA) to FDA for Non-Inferiority Study of ONS-5010 (GlobeNewswire) +9.73%
Dec-06-23 08:05AM	Outlook Therapeutics Announces Strategic Organizational Realignment (GlobeNewswire)
Nov-27-23 08:05AM	Outlook Therapeutics Announces Receipt of Type A Meeting Minutes and Reiterates Regulatory Path Forward for ONS-5010 (GlobeNewswire)
06:30AM	OTLK INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Outlook Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Case (GlobeNewswire)
02:04PM	Loading…
Nov-15-23 02:04PM	OTLK STOCKHOLDERS: Contact Robbins LLP for Information About Your Rights Against Outlook Therapeutics, Inc. (Business Wire)
Nov-14-23 08:05AM	Outlook Therapeutics Adds Global Commercial Expertise with Appointment of Jedd Comiskey as Senior VP - Head of Europe (GlobeNewswire) +8.83%
Nov-09-23 08:52AM	12 Best Day Trading Stocks To Buy (Insider Monkey) -11.00%
Nov-02-23 08:05AM	Outlook Therapeutics Provides Update on Type A Meetings with FDA (GlobeNewswire) -46.24%
Nov-01-23 08:05AM	Outlook Therapeutics to Present at Guggenheim's 5th Annual Inflammation, Neurology & Immunology (INI) Conference (GlobeNewswire) +5.40%
Oct-17-23 05:22PM	Outlook Therapeutics Investors: Company Investigated by the Portnoy Law Firm (GlobeNewswire) +14.51%
Oct-11-23 05:49PM	Outlook Therapeutics Investors: Company Investigated by the Portnoy Law Firm (GlobeNewswire)
Sep-29-23 08:05AM	Outlook Therapeutics Requests Type A Meeting With FDA (GlobeNewswire)
Sep-21-23 08:05AM	Outlook Therapeutics® to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference (GlobeNewswire)
Sep-05-23 08:05AM	Outlook Therapeutics® to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-31-23 10:15AM	Biotech Stock Roundup: FGEN Down on Study Failure, BMY Drug's Label Expansion & More (Zacks) -15.08%
Aug-30-23 06:11AM	US FDA declines to approve Outlook Therapeutics' eye disease drug (Reuters) -80.96%
06:00AM	Outlook Therapeutics® Provides Regulatory Update on FDA Review of ONS-5010 / LYTENAVA (bevacizumab-vikg) for the Treatment of Wet AMD (GlobeNewswire)
Aug-28-23 11:47AM	Outlook Therapeutics (OTLK): A Deep Dive into its Overvalued Status (GuruFocus.com) +10.34%
Aug-14-23 09:55AM	Should You Buy Outlook Therapeutics (OTLK) Ahead of Earnings? (Zacks)
08:05AM	Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2023 and Reiterates Key Anticipated Near-Term Milestones (GlobeNewswire)
Aug-01-23 08:45AM	Outlook Therapeutics® to Present at the BTIG Virtual Biotechnology Conference 2023 (GlobeNewswire)
Jun-11-23 08:45AM	When Will Outlook Therapeutics, Inc. (NASDAQ:OTLK) Turn A Profit? (Simply Wall St.)
Jun-06-23 01:59PM	Why Shares of Outlook Therapeutics Rose Tuesday (Motley Fool)
May-15-23 08:05AM	Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2023 and Provides Corporate Update (GlobeNewswire)
Apr-27-23 08:05AM	Outlook Therapeutics® to Present at the H.C. Wainwright BioConnect Investor Conference (GlobeNewswire)
Apr-10-23 11:43AM	Outlook Therapeutics, Inc.'s (NASDAQ:OTLK) top owners are individual investors with 37% stake, while 27% is held by private equity firms (Simply Wall St.)
Mar-13-23 07:00AM	Outlook Therapeutics® Confirms It Has No Exposure to Silicon Valley Bank (GlobeNewswire)
Feb-14-23 08:05AM	Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2023 and Provides Corporate Update (GlobeNewswire)
Feb-07-23 08:05AM	Outlook Therapeutics® to Present at the SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-19-23 08:05AM	Outlook Therapeutics® Strengthens Medical Affairs and Commercial Expertise with Appointments of Surendra Sharma, MD, Senior Vice President of Medical Affairs and Glen Olsheim, Executive Director of Commercial Excellence (GlobeNewswire)
Jan-11-23 01:00PM	JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th (ACCESSWIRE)
Jan-09-23 08:05AM	Outlook Therapeutics® to Present at the Virtual Investor 2023 Companies to Watch Event (GlobeNewswire)
Jan-02-23 07:31AM	Breakeven On The Horizon For Outlook Therapeutics, Inc. (NASDAQ:OTLK) (Simply Wall St.)
Dec-29-22 09:05AM	Outlook Therapeutics® Reports Financial Results for Fiscal Year 2022 and Provides Corporate Update (GlobeNewswire) +5.94%
Dec-23-22 09:00AM	Outlook Therapeutics® Enters Definitive Agreement for $31.8 Million Unsecured Convertible Promissory Note (GlobeNewswire) +21.81%
06:00AM	Outlook Therapeutics Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
Dec-22-22 08:05AM	Outlook Therapeutics® Announces Validation of Marketing Authorization Application by the European Medicines Agency for ONS-5010 as a Treatment for Wet AMD (GlobeNewswire)
Dec-01-22 08:05AM	Outlook Therapeutics® to Participate in the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & Medtech Conference (GlobeNewswire)
Nov-22-22 08:05AM	Outlook Therapeutics® to Present at the BTIG Ophthalmology Day (GlobeNewswire)
Nov-01-22 09:55AM	Outlook Therapeutics, Inc.'s (NASDAQ:OTLK) top owners are individual investors with 38% stake, while 25% is held by private equity firms (Simply Wall St.)
Oct-28-22 08:05AM	Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD (GlobeNewswire) -9.47%
Oct-05-22 06:09AM	Independent Director Kurt Hilzinger Just Bought 33% More Shares In Outlook Therapeutics, Inc. (NASDAQ:OTLK) (Simply Wall St.)
Sep-27-22 08:05AM	Outlook Therapeutics® and AmerisourceBergen Announce Strategic Commercialization Agreement for ONS-5010 for the Treatment of Wet AMD (GlobeNewswire)
Sep-26-22 08:35AM	Outlook Therapeutics® to Present at Eyecelerator @ AAO 2022 (GlobeNewswire)
Sep-07-22 08:05AM	Outlook Therapeutics® to Present at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-30-22 09:39AM	Outlook Therapeutics Shares Pop After Filing US Application For Its Lead Eye Disease Candidate (Benzinga)
08:05AM	Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration (GlobeNewswire)
Aug-15-22 08:05AM	Outlook Therapeutics Strengthens Board of Directors with Appointment of Julia A. Haller, MD (GlobeNewswire) +5.00%
Aug-10-22 08:05AM	Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2022 and Reiterates Key Anticipated Near-Term Milestones (GlobeNewswire)
Aug-04-22 08:05AM	Outlook to Present at the H.C. Wainwright 2nd Annual Ophthalmology Conference (GlobeNewswire)
Jul-26-22 07:18AM	When Will Outlook Therapeutics, Inc. (NASDAQ:OTLK) Become Profitable? (Simply Wall St.)
Jul-05-22 08:05AM	Outlook Therapeutics Announces Full Cash Pre-Payment of Convertible Promissory Note (GlobeNewswire) +7.84%
Jun-14-22 08:05AM	Outlook Therapeutics Confirms Status of Biologics License Application (BLA) Submission for ONS-5010 (GlobeNewswire) +15.95%
May-31-22 08:05AM	Outlook Therapeutics Provides Update on Biologics License Application (BLA) Submission for ONS-5010 as a Treatment for Wet AMD (GlobeNewswire) -31.95%
May-27-22 07:25AM	Bullish Outlook Therapeutics, Inc. (NASDAQ:OTLK) insiders filled their treasuries with US$557k worth of stock over last year (Simply Wall St.) +7.64%
May-18-22 08:05AM	Outlook Therapeutics to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire) -6.13%
May-13-22 08:05AM	Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2022 and Provides Corporate Update (GlobeNewswire) +7.38%
May-10-22 08:35AM	Outlook Therapeutics to Participate in Retina World Congress 2022 (GlobeNewswire)
May-09-22 08:35AM	Outlook Therapeutics to Participate at the Virtual Investor 2022 CEO Spotlight (GlobeNewswire) -7.50%
May-04-22 12:02PM	Here's What Outlook Therapeutics, Inc.'s (NASDAQ:OTLK) Shareholder Ownership Structure Looks Like (Simply Wall St.)
Apr-22-22 08:05AM	BioLexis Reorganization Results in GMS Holdings as Largest Shareholder in Outlook Therapeutics (GlobeNewswire)
Apr-05-22 08:05AM	Outlook Therapeutics to Present at Wet AMD and DME Drug Development Summit (GlobeNewswire)
Apr-04-22 07:45PM	Is Outlook Therapeutics (NASDAQ:OTLK) Using Too Much Debt? (Simply Wall St.)
Mar-31-22 08:05AM	Outlook Therapeutics Submits Biologics License Application to the U.S. Food and Drug Administration for ONS-5010 as a Treatment for Wet AMD (GlobeNewswire) -10.55%
Mar-03-22 08:05AM	Outlook Therapeutics Bolsters Commercialization Expertise with Appointment of Alicia Tozier as Senior Vice President of Marketing and Market Access (GlobeNewswire) +5.29%
Feb-24-22 08:05AM	Outlook Therapeutics to Present at the RANZCO 52nd Annual Scientific Congress (GlobeNewswire) +16.31%
Feb-16-22 10:59AM	When Will Outlook Therapeutics, Inc. (NASDAQ:OTLK) Become Profitable? (Simply Wall St.) +7.14%
Feb-14-22 08:05AM	Outlook Therapeutics Reports Financial Results for First Quarter Fiscal Year 2022 and Provides Corporate Update (GlobeNewswire)
Feb-10-22 08:05AM	Outlook Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference (GlobeNewswire)
Feb-08-22 08:05AM	Outlook Therapeutics Expands Commercial Team with Appointment of Senior Vice President of Commercial Operations (GlobeNewswire)
Feb-02-22 05:38PM	KWB Wealth Buys SPDR Portfolio S&P 600 Small Cap ETF, SPDR Portfolio Short Term Corporate ... (GuruFocus.com) -6.71%
08:05AM	Outlook Therapeutics to Present at the Fourth Annual Telluride Retina Film Festival (GlobeNewswire)
Jan-25-22 08:05AM	Outlook Therapeutics Provides a Corporate Update and Business Outlook (GlobeNewswire)
Jan-19-22 08:05AM	Outlook Therapeutics to Present at the Virtual Investor 2022 Top Picks Conference (GlobeNewswire)

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Haddadin Yezan Munther	Director	Mar 28 '24	Buy	11.82	1,882	22,242	5,049	Mar 29 10:39 AM
Evanson Jeff	CHIEF COMMERCIAL OFFICER	Mar 07 '24	Buy	0.42	62,484	26,243	808,459	Mar 11 04:43 PM

OTLK

Outlook Therapeutics Inc

Upgrade your FINVIZ experience